Laborie Medical Technologies Takes a Major Step in Urology Care
Laborie Medical Technologies Corp has recently made a significant advancement in the field of urology. The American Medical Association (AMA) has issued a new Category 1 Current Procedural Terminology (CPT) code specifically for the innovative Optilume® BPH Catheter System. This landmark decision indicates the growing recognition of Laborie's commitment to improving patient outcomes in the treatment of benign prostatic hyperplasia (BPH).
What is the Optilume® BPH Catheter System?
The Optilume® BPH Catheter System leverages a minimally invasive surgical therapy (MIST) to address lower urinary tract symptoms (LUTS) that arise from BPH. This cutting-edge technology utilizes a proprietary double-lobe balloon for mechanical dilation alongside the localized delivery of paclitaxel, a key component for treatment efficiency. The combination of these techniques allows for effective symptom relief and promotes quicker recovery for patients dealing with BPH-induced issues.
Why the New CPT Code Matters
With the issuance of the CPT code 52XX2, healthcare providers will be able to report this procedure, facilitating straightforward reimbursement processes from health insurance providers. This milestone is vital as it enhances accessibility to the Optilume BPH treatment, allowing more men to benefit from this significant advancement in urological care. Michael Frazzette, Laborie's President and CEO, expressed pride in this achievement, stating it will open doors for broader patient access and adoption of this necessary procedure.
Clinical Trials and Results
Data from clinical trials have shown that the Optilume BPH Catheter System results in the highest Qmax recorded in its category, achieving an impressive 19 mL/sec at the two-year mark. This result is instrumental in reshaping the treatment approach for BPH, providing immediate relief that lasts and minimizing the recovery burden on patients. This device was developed as a direct response to feedback from patients and healthcare providers who expressed dissatisfaction with traditional treatment options.
Future Perspectives
Starting January 1, 2026, the Optilume BPH Catheter System will be eligible for reporting under the newly issued CPT code. This change is significant not only for Laborie but for the wider medical community as it helps to standardize treatment for BPH across various healthcare settings. CPT codes facilitate the categorization of medical services and enhance the accuracy of billing and reimbursements, thus playing a crucial role in the healthcare industry.
About Laborie Medical Technologies
Laborie Medical Technologies, with its headquarters based in Portsmouth, continues to lead the charge in developing innovative medical solutions across several specializations, including Urology and Gastroenterology. The company is dedicated to manufacturing high-quality diagnostic and therapeutic products, providing healthcare professionals with the tools necessary to deliver optimal patient care. As a prominent player in the medical technology landscape, Laborie not only focuses on product development but also prioritizes clinical education and information to ensure healthcare providers can use these advancements effectively.
Frequently Asked Questions
What is the significance of the new CPT code for Laborie?
The new CPT code expands reimbursement pathways for the Optilume BPH Catheter System, enhancing access to this innovative treatment.
How does the Optilume BPH Catheter System work?
This device combines mechanical dilation with targeted drug delivery to ease symptoms associated with BPH effectively.
When can the new CPT code be reported by healthcare providers?
The CPT code can be reported starting January 1, 2026, allowing providers to streamline billing for the Optilume BPH treatment.
What are the clinical trial results for the Optilume BPH device?
Clinical trials have shown that it achieves the highest Qmax of 19 mL/sec at a two-year follow-up, highlighting its effectiveness.
What is Laborie's focus as a company?
Laborie aims to develop quality medical technology across specialties like Urology, supporting clinicians with effective diagnostic and therapeutic solutions.
